CJC-1295 Without DAC
Well StudiedGHRH analog
CJC-1295 without DAC (Mod GRF 1-29) is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids. It has been studied in endocrinology research for its effects on growth hormone releasing hormone receptor activation. Unlike CJC-1295 with DAC, it lacks the Drug Affinity Complex, resulting in a shorter half-life. Published research has examined its pharmacological profile. RaysunPeptide supplies CJC-1295 without DAC for qualified research and laboratory applications.
Mechanism of Action
Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.
Key Benefits
Molecular Data
Dosing Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Anti-Aging/Wellness | 100mcg | 2x daily (morning and bedtime) | SubQ |
| Body Composition | 100-150mcg | 3x daily (morning, post-workout, bedtime) | SubQ |
| Maximum GH Release | 200mcg | 2-3x daily with GHRP | SubQ |
| Sleep Enhancement | 100-200mcg | Once at bedtime | SubQ |
Research Indications
Growth Hormone
Restores natural GH pulsatility patterns in aging individuals.
Elevates IGF-1 through enhanced GH secretion.
Supports pituitary axis without suppression of natural function.
Anti-Aging
Supports maintenance of lean muscle mass through GH elevation.
Supports bone health through GH-mediated pathways.
Improvements in skin quality through collagen synthesis.
Recovery
Enhanced recovery from training through GH elevation.
Improved sleep architecture with bedtime dosing.
Peptide Interactions
Complementary GH release via different receptor pathways. Popular combination.
Amplifies GH pulse when combined.
Potent combination maximizing GH through dual pathways.
Can combine but watch for excessive GH elevation.
Choose one variant based on desired release kinetics.
Both are GHRH analogs; combining offers no additional benefit.
Different mechanisms; continuous ghrelin versus pulsatile GHRH.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Generally well-tolerated at recommended doses
- •Temporary facial flushing/warmth (5-10 minutes post-injection)
Stop Signs (Seek Medical Attention)
- ⚠Persistent joint pain or carpal tunnel symptoms
- ⚠Significant water retention or edema
- ⚠Unexplained headaches or vision changes
- ⚠Extreme fatigue or lethargy
- ⚠Allergic reaction signs at injection sites
Contraindications
- ✕Active cancer (due to growth-promoting effects)
- ✕Diabetic retinopathy
- ✕Severe kidney disease
- ✕Pregnancy or breastfeeding
Quality Checklist
Good Signs ✓
- Vendor provides certificates of analysis (>98% purity)
- Proper cold-chain shipping with ice packs/refrigeration
- Vacuum-sealed vials showing pressure seal integrity
- White/off-white lyophilized powder
Warning Signs !
- Verify expiration dates; lyophilized peptides stable ~2 years if stored properly
Bad Signs ✕
- Pre-reconstituted solutions—peptide degrades rapidly
- Discolored powder (yellow/brown indicates degradation)
- Cloudy solution after reconstitution
References
Identified CJC-1295 as a tetrasubstituted hGRF(1-29) analog that covalently binds albumin. Showed 4-fold increase in GH area under the curve compared to native hGRF(1-29) in rat pituitary cells.
View on PubMed →Single injection of CJC-1295 produced dose-dependent 2- to 10-fold increases in GH for 6+ days and 1.5- to 3-fold increases in IGF-I for 9-11 days in healthy adults. Estimated half-life of 5.8-8.1 days.
View on PubMed →GH secretion was increased after CJC-1295 with preserved pulsatility. Basal (trough) GH levels were markedly increased (7.5-fold), demonstrating that CJC-1295 maintains natural GH pulse patterns.
View on PubMed →Once-daily CJC-1295 maintained normal body composition and growth in GHRH knockout mice, demonstrating efficacy in restoring GH axis function in GH-deficient animal models.
View on PubMed →CJC-1295 administration in normal adults activated the GH/IGF-1 axis and produced measurable serum protein profile changes, providing biomarker evidence for sustained GHRH analog activity.
View on PubMed →FAQs
How many times per day should CJC-1295 (without DAC) be injected?
CJC-1295 without DAC typically requires 2-3 injections daily (morning, post-workout optional, and bedtime) with 100-300mcg per dose to maintain GH elevation. The 30-minute to 2-hour half-life necessitates multiple daily injections, unlike the weekly DAC variant.
What time of day is best to inject CJC-1295 without DAC?
Optimal timing is upon waking on an empty stomach and before bedtime, with an optional post-workout injection. Inject 30+ minutes away from food to maximize GH release. Bedtime dosing is particularly effective as it amplifies natural sleep-associated GH pulses.
Does CJC-1295 without DAC maintain natural GH pulsatility unlike the DAC version?
Yes, the non-DAC version preserves natural pulsatile GH secretion patterns with its 30-minute half-life, whereas DAC provides continuous elevation. This pulsatility is closer to physiology and results in fewer side effects like joint pain compared to continuous DAC stimulation, making it popular for anti-aging protocols.
Can CJC-1295 be stacked with GHRP peptides for better results?
Yes, combining CJC-1295 without DAC with GHRP-6 or GHRP-2 creates a synergistic 'stack' where the GHRH and GHRP work through complementary pathways to amplify GH release significantly beyond either peptide alone. This is the classic approach for maximizing growth hormone stimulation.
